Posted on Nov 25, 2022

Cerca Biotech was well represented last week at both MEDICA 2022 and the EBCC13 meeting in Barcelona.

Interest in MammaTyper® at MEDICA

MEDICA was back in full swing after a very tentative re-start last year. We had visitors to our stand from across the world.

The interest was for both our MammaTyper® RT-PCR breast cancer subtyping assay and the newly released CercaTest Pre-eclampsia Vue™ point of care test.

A steady flow of distributors and clinicians kept us very busy, with lots to follow up on this week.

Breast cancer innovation showcased at EBCC

The 13th European Breast Cancer Conference (EBCC) in Barcelona saw clinicians involved in breast cancer care from across Europe and beyond descend on Barcelona for a three-day meeting. With a full agenda of topics covering diagnosis, surgery and treatment.

It was great to showcase our new exhibition stand and talk over coffee with a number of interested parties.

The standout event for the week was our first international round table on Wednesday evening, where all key clinician groups were represented at a presentation of this year’s poster data from EBCC.

Prof. Abeer Shaaban, Regina Pinto and Vinicio Tassani, presented data from the UK, Portugal and China. The theme of these presentations focused heavily on the corelation of MammaTyper® with immunohistochemistry (IHC). As well as MammaTyper’s® use in HER2 status determination, especially the HER2-Low subgroup.

There was lively discussion and plenty of in-depth examination of the data. What is clear is that, outside of the USA, there is still a need to seriously consider how IHC can identify this group of patients both at the 2+/3+ interface, and at the bottom of the range, at the 1+cut off.

We believe MammaTyper® fills this requirement perfectly, as we have shown in our research and retrospective data from many thousands of patients.

A step forward in the world of breast cancer care

This was a great week for Cerca Biotech, and now we’re back into the busy world of oncology at its best! We finished the week energised and ready to keep working to make sure that breast cancer diagnostics can be revolutionised using modern technology.